Evidence map›Paper›PMID 31973204›Full record

ArticleBrain sciences2020

Clinical Outcomes of MLC601 (NeuroAiD

Asra Al Fauzi, Krisna Tsaniadi Prihastomo, I G M Aswin R Ranuh, Tedy Apriawan, Joni Wahyuhadi, M Arifin Parenrengi, Agus Turchan, Abdul Hafid Bajamal, Hari Basuki Notobroto

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. NeuroAiDBiomedicines · 2024
    Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Asra Al FauziDepartment of Neurosurgery, Faculty of Medicine, Universitas Airlangga-Dr. Soetomo General Academic Hospital, Surabaya Neuroscience Institute, Surabaya 60286, Indonesia.
Krisna Tsaniadi PrihastomoDepartment of Neurosurgery, Dr. Kariadi Hospital Medical Center, Faculty of Medicine, Diponegoro University, 50111 Semarang, Indonesia.
I G M Aswin R RanuhDepartment of Neurosurgery, Faculty of Medicine, Universitas Airlangga-Dr. Soetomo General Academic Hospital, Surabaya Neuroscience Institute, Surabaya 60286, Indonesia.
Tedy ApriawanDepartment of Neurosurgery, Faculty of Medicine, Universitas Airlangga-Dr. Soetomo General Academic Hospital, Surabaya Neuroscience Institute, Surabaya 60286, Indonesia.
Joni WahyuhadiDepartment of Neurosurgery, Faculty of Medicine, Universitas Airlangga-Dr. Soetomo General Academic Hospital, Surabaya Neuroscience Institute, Surabaya 60286, Indonesia.
M Arifin ParenrengiDepartment of Neurosurgery, Faculty of Medicine, Universitas Airlangga-Dr. Soetomo General Academic Hospital, Surabaya Neuroscience Institute, Surabaya 60286, Indonesia.
Agus TurchanDepartment of Neurosurgery, Faculty of Medicine, Universitas Airlangga-Dr. Soetomo General Academic Hospital, Surabaya Neuroscience Institute, Surabaya 60286, Indonesia.
Abdul Hafid BajamalDepartment of Neurosurgery, Faculty of Medicine, Universitas Airlangga-Dr. Soetomo General Academic Hospital, Surabaya Neuroscience Institute, Surabaya 60286, Indonesia.
Hari Basuki NotobrotoDepartment of Biostatistics and Population Studies, Faculty of Public Health, Universitas Airlangga, 60111 Surabaya, Indonesia.
Airlangga University · IDDr. Kariadi Hospital · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMLC601 is a natural product formulation from Chinese medicine that is extensively studied in ischemic stroke. Traumatic brain injury (TBI) shares pathophysiological mechanisms with ischemic stroke, yet there are few studies on the use of MLC601 in treating TBI. This Indonesian pilot study aimed to investigate clinical outcomes of MLC601 for TBI.

methodsThis randomized controlled trial included subjects with nonsurgical moderate TBI allocated into two groups: with and without MLC601 over three months in addition to standard TBI treatment. Clinical outcomes were measured by the Glasgow Outcome Scale (GOS) and Barthel Index (BI) observed upon discharge and at months (M) 3 and 6.

resultsThirty-two subjects were included. The MLC601 group (

conclusionIn this cohort of nonsurgical moderate TBI subjects, MLC601 showed potential for a positive effect on clinical outcome with no adverse effects.

Indexed as

clinical outcomeMLC601nonsurgical lesiontraumatic brain injury

Identifiers

PMID31973204
PMCPMC7071378
OpenAlexW3001674645

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.